As is generally the case for many areas of the stock market, summer marks a pronounced slowdown in newsflow and stock action for the healthcare sector. Although these periods can be frustrating for investors and traders who crave action, the sluggish pace of trading can afford others an opportunity to get caught up on due diligence and begin establishing positions.

Investopedia Broker Guides: Enhance your trading with the tools from today's top online brokers.

Two Significant Cancer Companies Heading in Opposite Directions
With little of note on the horizon on this weekend, a quick look back at last week seems in order as it was a notable week for at least two oncology-focused biotechnology companies.

Dendreon (Nasdaq:DNDN) reported yet another disappointing quarter; a quarter that saw not only a significant restructuring announcement, but also a sequential decline in sales of the controversial cancer vacine Provenge. Although lauded as a first-of-its-kind therapy, Provenge has simply not caught on with the oncology community - likely due to a combination of its unconventional nature and the lack of response seen in traditional indicators (Provenge doesn't appreciably shrink tumors or lower PSA levels). While management believes that its latest round of cuts will allow the company to break even at $100 million in quarterly sales, very competitive new drugs from Johnson & Johnson (NYSE:JNJ) and Medivation (Nasdaq:MDVN) may make even that level of revenue production difficult.

SEE: How To Choose A Healthcare Plan

Speaking of Medivation, the company announced last weak that the FDA has set a PDUFA date for its heralded prostate cancer drug enzalutamide. On or about November 22, investors will know whether the FDA has approved the drug for sale in the United States or whether Medivation (and partner Astellas) will have to submit additional data.

The K-V Story Ends with a Whimper
This past weekend also saw the likely end of former controversial specialty drug company K-V Pharmaceutical, as the company declared Chapter 11 bankruptcy.

SEE: An Overview Of Corporate Bankruptcy

K-V had largely bet the company's future on Makena - a drug designed to prevent premature births. The controversy came from the fact that K-V had conducted trials and sought approval for Makena as an orphan drug, but compounding pharmacies had been producing the treatment (legally) for patients for years. Whereas pharmacies were charging $300 or less for a course of treatment, K-V initially tried to price Makena at around $25,000 without offering any appreciable improvement in safety or efficacy (rather, just the consistency of a single manufactured product versus the potential variability from compounding pharmacies).

K-V tried to enlist the FDA to eliminate the cheaper competition and force compounding pharmacies to cease selling their cheaper generic alternative as part of the orphan drug designation, but widespread public outrage (including the involvement of Congress) and an unclear legal precedent ultimately led the FDA to back down. K-V tried to reprice the drug (cutting the price by more than half), but could not gain any headway.

SEE: 5 Things To Know About Managing Your Healthcare Deductible

The Bottom Line
The performance of healthcare stocks (as measured by ETFs) has begun to falter a bit. The Health Care Select Sector SPDR (ARCA:XLV) is up around 9.3% year-to-date, slipping below the the 9.7% return of the S&P 500. The iShares Dow Jones US Pharmaceuticals ETF (ARCA:IHE) is up 12.6%, while the iShares Dow Jones US Medical Devices ETF (ARCA:IHI) is up 8.1%. The SPDR S&P Biotech ETF (ARCA:XBI) has risen more than 30% year-to-date.

At the time of writing, Stephen D. Simpson did not own shares in any of the companies mentioned in this article.

Related Articles
  1. Investing Basics

    Top Tips for Diversifying with Exotic Currencies

    Is there an opportunity in exotic currencies right now, or are you safer sticking to the major ones?
  2. Mutual Funds & ETFs

    The 3 Biggest Mutual Fund Companies in the US

    Compare and contrast the rise of America's big three institutional asset managers: BlackRock Funds, The Vanguard Group and State Street Global Advisors.
  3. Stock Analysis

    The 5 Best Dividend Stocks in the Healthcare Sector

    Learn about the top five dividend stocks of companies operating in the health care sector that generate substantial cash flows to afford high payouts.
  4. Stock Analysis

    3 Stocks that Are Top Bets for Retirement

    These three stocks are resilient, fundamentally sound and also pay generous dividends.
  5. Professionals

    5 Top-Rated Funds for Your Retirement Portfolio

    Mutual funds are a good choice for emotional investors. Here are five popular funds to consider.
  6. Investing News

    Are Stocks Cheap Now? Nope. And Here's Why

    Are stocks cheap right now? Be wary of those who are telling you what you want to hear. Here's why.
  7. Investing News

    4 Value Stocks Worth Your Immediate Attention

    Here are four stocks that offer good value and will likely outperform the majority of stocks throughout the broader market over the next several years.
  8. Investing News

    These 3 High-Quality Stocks Are Dividend Royalty

    Here are three resilient, dividend-paying companies that may mitigate some worry in an uncertain investing environment.
  9. Stock Analysis

    An Auto Stock Alternative to Ford and GM

    If you're not sure where Ford and General Motors are going, you might want to look at this auto investment option instead.
  10. Mutual Funds & ETFs

    The 4 Best Buy-and-Hold ETFs

    Explore detailed analyses of the top buy-and-hold exchange traded funds, and learn about their characteristics, statistics and suitability.
  1. Can mutual funds invest in IPOs?

    Mutual funds can invest in initial public offerings (IPOS). However, most mutual funds have bylaws that prevent them from ... Read Full Answer >>
  2. How do dividends affect retained earnings?

    When a company issues a cash dividend to its shareholders, the retained earnings listed on the balance sheet are reduced ... Read Full Answer >>
  3. What is the difference between called-up share capital and paid-up share capital?

    The difference between called-up share capital and paid-up share capital is investors have already paid in full for paid-up ... Read Full Answer >>
  4. Why would a corporation issue convertible bonds?

    A convertible bond represents a hybrid security that has bond and equity features; this type of bond allows the conversion ... Read Full Answer >>
  5. Does index trading increase market vulnerability?

    The rise of index trading may increase the overall vulnerability of the stock market due to increased correlations between ... Read Full Answer >>
  6. What does a high turnover ratio signify for an investment fund?

    If an investment fund has a high turnover ratio, it indicates it replaces most or all of its holdings over a one-year period. ... Read Full Answer >>

You May Also Like

Trading Center
You are using adblocking software

Want access to all of Investopedia? Add us to your “whitelist”
so you'll never miss a feature!